[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @Dyne_tx Dyne Therapeutics Dyne Therapeutics posts on X about has been, japan, breakthrough, $dyn the most. They currently have XXXXX followers and XX posts still getting attention that total XX engagements in the last XX hours. ### Engagements: XX [#](/creator/twitter::1080495985304973314/interactions)  - X Week XXX -XX% - X Month XXXXX +60% - X Months XXXXXX +5.90% - X Year XXXXXX -XX% ### Mentions: X [#](/creator/twitter::1080495985304973314/posts_active)  - X Week XX -XX% - X Month XX -XX% - X Months XX -XX% - X Year XXX +51% ### Followers: XXXXX [#](/creator/twitter::1080495985304973314/followers)  - X Week XXXXX +0.08% - X Month XXXXX +0.64% - X Months XXXXX +7% - X Year XXXXX +9.70% ### CreatorRank: undefined [#](/creator/twitter::1080495985304973314/influencer_rank)  ### Social Influence [#](/creator/twitter::1080495985304973314/influence) --- **Social category influence** [stocks](/list/stocks) X% [countries](/list/countries) XXXX% [finance](/list/finance) XXXX% **Social topic influence** [has been](/topic/has-been) 1.33%, [japan](/topic/japan) 1.33%, [breakthrough](/topic/breakthrough) 1.33%, [$dyn](/topic/$dyn) 1.33%, [investment](/topic/investment) XXXX% **Top accounts mentioned or mentioned by** [@myotonicstrong](/creator/undefined) [@checkorphan](/creator/undefined) [@jettfoundation](/creator/undefined) [@mdaorg](/creator/undefined) [@usfda](/creator/undefined) [@parentprojectmd](/creator/undefined) [@cureduchenne](/creator/undefined) [@parentprojectmds](/creator/undefined) [@parentproject](/creator/undefined) [@worldsymposia](/creator/undefined) [@eucommission](/creator/undefined) [@fshdsociety](/creator/undefined) [@pegsboston](/creator/undefined) [@dppspain](/creator/undefined) [@muscleandnerve](/creator/undefined) [@icnmdcongress](/creator/undefined) [@malifesciences](/creator/undefined) [@dynetx](/creator/undefined) [@roche](/creator/undefined) [@trindsnmd](/creator/undefined) **Top assets mentioned** [Dyne Therapeutics, Inc. Common Stock (DYN)](/topic/$dyn) ### Top Social Posts [#](/creator/twitter::1080495985304973314/posts) --- Top posts by engagements in the last XX hours "DYNE-251 has been granted Orphan Drug designation in Japan for the treatment of patients with #Duchenne muscular dystrophy (#DMD) who have mutations in the DMD gene that are amenable to exon XX skipping. Read here:" [X Link](https://x.com/Dyne_tx/status/1972644303873712392) [@Dyne_tx](/creator/x/Dyne_tx) 2025-09-29T12:47Z 1251 followers, XXX engagements "Today we announced that the @US_FDA has granted Breakthrough Therapy Designation to DYNE-251 for the treatment of patients with DMD amenable to exon XX skipping. Read here:" [X Link](https://x.com/Dyne_tx/status/1952348821700120651) [@Dyne_tx](/creator/x/Dyne_tx) 2025-08-04T12:40Z 1250 followers, XXX engagements "Were pleased to share new positive data from our Phase 1/2 DELIVER trial of DYNE-251 in DMD at the @MDAorg Conference. Learn more: $DYN" [X Link](https://x.com/Dyne_tx/status/1901600682899353668) [@Dyne_tx](/creator/x/Dyne_tx) 2025-03-17T11:45Z 1251 followers, XXX engagements "Data from the ongoing Phase 1/2 ACHIEVE trial in DM1 to be presented at the Congress of the @WorldMuscleSoc continue to demonstrate a favorable safety and efficacy profile for zeleciment basivarsen (formerly known as DYNE-101). See the data:" [X Link](https://x.com/Dyne_tx/status/1975321446650991006) [@Dyne_tx](/creator/x/Dyne_tx) 2025-10-06T22:05Z 1249 followers, XXX engagements "Kathleen Tregoning joined us for our FORCEs in Biotech series sharing insights on government affairs: Government affairs isnt bowlingits billiards. Every move every conversation every engagement bounces off another. Its all connected" [X Link](https://x.com/Dyne_tx/status/1978484034243039739) [@Dyne_tx](/creator/x/Dyne_tx) 2025-10-15T15:32Z 1249 followers, XXX engagements "Were pleased to welcome Brian Posner to Dynes Board of Directors. His 30+ years of executive and investment leadership will help guide our mission to deliver functional improvement for people living with neuromuscular diseases. Read more:" [X Link](https://x.com/Dyne_tx/status/1973842614387450115) [@Dyne_tx](/creator/x/Dyne_tx) 2025-10-02T20:08Z 1251 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@Dyne_tx Dyne Therapeutics
Dyne Therapeutics posts on X about has been, japan, breakthrough, $dyn the most. They currently have XXXXX followers and XX posts still getting attention that total XX engagements in the last XX hours.
Engagements: XX #
- X Week XXX -XX%
- X Month XXXXX +60%
- X Months XXXXXX +5.90%
- X Year XXXXXX -XX%
Mentions: X #
- X Week XX -XX%
- X Month XX -XX%
- X Months XX -XX%
- X Year XXX +51%
Followers: XXXXX #
- X Week XXXXX +0.08%
- X Month XXXXX +0.64%
- X Months XXXXX +7%
- X Year XXXXX +9.70%
CreatorRank: undefined #
Social Influence #
Social category influence stocks X% countries XXXX% finance XXXX%
Social topic influence has been 1.33%, japan 1.33%, breakthrough 1.33%, $dyn 1.33%, investment XXXX%
Top accounts mentioned or mentioned by @myotonicstrong @checkorphan @jettfoundation @mdaorg @usfda @parentprojectmd @cureduchenne @parentprojectmds @parentproject @worldsymposia @eucommission @fshdsociety @pegsboston @dppspain @muscleandnerve @icnmdcongress @malifesciences @dynetx @roche @trindsnmd
Top assets mentioned Dyne Therapeutics, Inc. Common Stock (DYN)
Top Social Posts #
Top posts by engagements in the last XX hours
"DYNE-251 has been granted Orphan Drug designation in Japan for the treatment of patients with #Duchenne muscular dystrophy (#DMD) who have mutations in the DMD gene that are amenable to exon XX skipping. Read here:"
X Link @Dyne_tx 2025-09-29T12:47Z 1251 followers, XXX engagements
"Today we announced that the @US_FDA has granted Breakthrough Therapy Designation to DYNE-251 for the treatment of patients with DMD amenable to exon XX skipping. Read here:"
X Link @Dyne_tx 2025-08-04T12:40Z 1250 followers, XXX engagements
"Were pleased to share new positive data from our Phase 1/2 DELIVER trial of DYNE-251 in DMD at the @MDAorg Conference. Learn more: $DYN"
X Link @Dyne_tx 2025-03-17T11:45Z 1251 followers, XXX engagements
"Data from the ongoing Phase 1/2 ACHIEVE trial in DM1 to be presented at the Congress of the @WorldMuscleSoc continue to demonstrate a favorable safety and efficacy profile for zeleciment basivarsen (formerly known as DYNE-101). See the data:"
X Link @Dyne_tx 2025-10-06T22:05Z 1249 followers, XXX engagements
"Kathleen Tregoning joined us for our FORCEs in Biotech series sharing insights on government affairs: Government affairs isnt bowlingits billiards. Every move every conversation every engagement bounces off another. Its all connected"
X Link @Dyne_tx 2025-10-15T15:32Z 1249 followers, XXX engagements
"Were pleased to welcome Brian Posner to Dynes Board of Directors. His 30+ years of executive and investment leadership will help guide our mission to deliver functional improvement for people living with neuromuscular diseases. Read more:"
X Link @Dyne_tx 2025-10-02T20:08Z 1251 followers, XXX engagements